Germany – Pharmaceutical products – Abschluss von Vereinbarungen zur wirtschaftlichen Versorgung von Kontrastmitteln im Rahmen eines Open House Modells

Health · Germany government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

November 30, 2027
Response Due
Active
Status

Opportunity Overview

Germany – Pharmaceutical products – Conclusion of agreements for the economical supply of contrast agents within the framework of an open house model

This Germany Pharmaceuticals opportunity is one most of your competitors will never see.

How to bid: GlobalGov tracks this tender; it does not accept bids. Submit your response through the issuing agency’s official notice.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start a free GlobalGov account

Solicitation Details

Issuing agencyHealth
CountryGermany
CategoryPharmaceuticals
PublishedSeptember 17, 2025
Procurement stageActive solicitation
Response dueNovember 30, 2027
StatusOpen — accepting responses
Original languageGerman — members read it in their own language
Official sourceView original notice
Last verifiedOctober 11, 2026

Source: Tenders Electronic Daily (TED), © European Union. Notice content reused under Commission Decision 2011/833/EU; editorial content licensed CC BY 4.0. GlobalGov is not affiliated with the European Union.

Related Opportunities in Germany

Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit der Wirkstoffkombination aus Oxycodon und Naloxon (ATC-Code: N02AA55).
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Aflibercept (ausgenommen 114,3 mg/ml), ATC S01LA05 für die Zeit 01.12.2025 - 30.11.2027
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Emtricitabin,Tenofovirdisoproxil und Rilpivirin, ATC J05AR08
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130 a Abs. 8 SGB V mit dem Wirkstoff Infliximab zur intravenösen Applikation
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Umeclidiniumbromid, ATC R03BB07
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Tocilizumab, ATC L04AC07
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Sulpirid, ATC N05AL01
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Latanoprost + Timolol (ausschließlich Einzeldosen), ATC S01ED61 für die Zeit 01.06.2025 - 31.05.2027

See every Germany Pharmaceuticals opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free Germany Pharmaceuticals intelligence report in your inbox

A personalized report on Germany Pharmaceuticals opportunities, emailed in 5-10 minutes. One per month, no account needed.